| Code | CSB-RA011649MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody BA-1106, targeting IL2RA (Interleukin-2 Receptor Alpha chain, also known as CD25). IL2RA serves as the alpha subunit of the high-affinity IL-2 receptor complex and plays a critical role in T cell-mediated immune responses by facilitating IL-2 signaling, which is essential for T cell proliferation, differentiation, and survival. The protein is constitutively expressed on regulatory T cells and becomes upregulated on activated T cells and B cells. Dysregulation of IL2RA expression is associated with various immunological disorders, including autoimmune diseases, transplant rejection, and hematological malignancies such as adult T-cell leukemia/lymphoma and certain B-cell lymphomas.
BA-1106, also known as Basiliximab, is an anti-IL2RA chimeric monoclonal antibody that occupies IL2RA and competitively blocks the binding of IL-2 to the high-affinity receptor, thus selectively inhibiting the activation and proliferation of T lymphocytes. Basiliximab is the first monoclonal antibody approved for clinical use and is mainly used to prevent acute rejection after kidney transplantation, providing strong early immunosuppression to help patients smoothly pass through the period with the highest risk of acute rejection. This biosimilar antibody provides researchers with a reliable tool for studying immune regulation, T cell activation mechanisms, and the role of IL2RA in disease pathogenesis. It supports investigations into therapeutic strategies targeting the IL-2/IL2RA axis in cancer immunotherapy and autoimmune conditions.
There are currently no reviews for this product.